Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Hirofumi, Suwa"'
Autor:
Masahiro Takada, Michio Yoshimura, Takeshi Kotake, Kosuke Kawaguchi, Ryuji Uozumi, Masako Kataoka, Hironori Kato, Hiroshi Yoshibayashi, Hirofumi Suwa, Wakako Tsuji, Hiroyasu Yamashiro, Eiji Suzuki, Masae Torii, Yosuke Yamada, Tatsuki Kataoka, Hiroshi Ishiguro, Satoshi Morita, Masakazu Toi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Radiation therapy (RT) can enhance the abscopal effect of immune checkpoint blockade. This phase I/II study investigated the efficacy and safety of nivolumab plus RT in HER2-negative metastatic breast cancer requiring palliative RT for bone
Externí odkaz:
https://doaj.org/article/7ba1e3013973440cb0f52afdf70ac247
Autor:
Nobuko Kawaguchi-Sakita, Noriko Senda, Yukiko Inagaki-Kawata, Hiromi Murakami, Sayaka Honda, Takahiro Yamada, Yuki Kataoka, Shoko Takahara, Shigeru Tsuyuki, Kazuhiko Yamagami, Yoshio Moriguchi, Masae Torii, Tatsushi Kato, Hirofumi Suwa, Wakako Tsuji, Eiji Suzuki, Akira Yamauchi, Ryuji Okamura, Shinji Kosugi, Masakazu Toi
Publikováno v:
Cancer Research. 83:P2-05
[Introduction] Personalized health care is recommended for the prevention and early detection of breast cancer. Advances in technology have made it possible to estimate genetic risk, PGV (pathogenic/likely-pathogenic germline variant) or PRS (polygen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::453971011d367876fdff63036c492ed5
https://doi.org/10.1158/1538-7445.sabcs22-p2-05-02
https://doi.org/10.1158/1538-7445.sabcs22-p2-05-02
Autor:
Takayuki Ueno, Louis W.C. Chow, Wonshik Han, Chiun Sheng Huang, G Bruce Mann, Satoshi Morita, Hironori Haga, Elham Fakhrejahani, Takayuki Kobayashi, Kenichi Inoue, Mariko Tokiwa, Hirofumi Suwa, Tomoyuki Aruga, Sachiko Minamiguchi, Yosuke Yamada, Yuko Tanabe, Masahiro Takada, Toshinari Yamashita, Hiroji Iwata, Chi-Feng Chung, Sachiko Takahara, Eriko Tokunaga, Shigeru Imoto, Eun Sook Lee, Yasuaki Sagara, Jee Hyun Kim, Richard H DeBoer, Hyun-Ah Kim, Hung Wen Lai, Ming-Feng Hou, Michelle White, Yoshiko Umeyama
Publikováno v:
Cancer Research. 83:P5-09
Background: Early biologic response to endocrine therapy, such as changes in Ki67 labeling index (LI), has been suggested to predict long-term outcomes in hormone sensitive breast cancer. The addition of a CDK4/6 inhibitor to endocrine therapy has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb53d5840e126a022215ca6a15039878
https://doi.org/10.1158/1538-7445.sabcs22-p5-09-01
https://doi.org/10.1158/1538-7445.sabcs22-p5-09-01
Autor:
Kosuke Kawaguchi, Yurina Maeshima, Hiroshi Ishiguro, Kazuhiko Yamagami, Sachiko Takahara, Hirofumi Suwa, Masae Torii, Shigenori Nagai, Yasuaki Sagara, Wakako Tsuji, Hiroyasu Yamashiro, Takeshi Kotake, Shinji Fukuda, Kuniaki Saito, Yasuko Yamamoto, Masako Kataoka, Yuki Himoto, Atsushi Yonezawa, Yukiko Fukui, Yuki Nakamura, Wei Li, Sunao Tanaka, Satoshi Morita, Masakazu Toi
Publikováno v:
Cancer Research. 83:P2-26
Background: Abemaciclib is a selective CDK4 and CDK6 inhibitor with demonstrated efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The most common adverse event across previous trials was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46920a12a9fec6673cb0aad9caebf21d
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-07
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-07
Autor:
Nina Odan, Yuichiro Kikawa, Hajime Matsumoto, Junya Minohata, Hirofumi Suwa, Takashi Hashimoto, Toshitaka Okuno, Masaru Miyashita, Masaru Saito, Kazuhiko Yamagami, Shintaro Takao
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 14 (2020)
Background: Clinical studies have shown that palbociclib improves progression-free survival in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) patients with advanced breast cancer (ABC). However, there
Externí odkaz:
https://doaj.org/article/e7749095d95342aab4ae9a2a27a24e9c
Publikováno v:
Breast Cancer. 30:309-314
We investigated the barriers to and promoters of taking BRCA testing, after the start of national healthcare insurance coverage for non-metastatic breast cancer patients in Japan.This was a multi-center, retrospective, cohort study. We included stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::646eb40bc76ea46f96074230d94589b2
https://doi.org/10.1007/s12282-022-01424-3
https://doi.org/10.1007/s12282-022-01424-3
Autor:
Kazuhiro Araki, Yoshinori Ito, Ippei Fukada, Kokoro Kobayashi, Yoshimasa Miyagawa, Michiko Imamura, Ayako Kira, Yuichi Takatsuka, Chiyomi Egawa, Hirofumi Suwa, Shinji Ohno, Yasuo Miyoshi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstracts Background Although peripheral blood-based parameters (PBBPs) are reported as prognostic indicators in patients with breast cancers, their utility has not been studied in human epidermal growth factor receptor 2 (HER2)-positive advanced bre
Externí odkaz:
https://doaj.org/article/29f5a70f15404664a88f5d345caa82d3
Publikováno v:
Anticancer Research. 43:1373-1375
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e29a0ad3e123f7e766deb1b65a60d6ab
https://doi.org/10.21873/anticanres.16285
https://doi.org/10.21873/anticanres.16285
Publikováno v:
Asian Journal of Surgery, Vol 43, Iss 11, Pp 1099-1100 (2020)
Externí odkaz:
https://doaj.org/article/f4a3c5c7014e4f968c423c5fbab48f31
Autor:
Hiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, Yasuhiro Okumura, Toshimi Takano, Eriko Tokunaga, Tsuyoshi Saito, Yasuaki Sagara, Kosuke Yamazaki, Yoshihiro Kawaguchi, Tecchuu Lee, Shinji Ozaki, Kazuhiko Yamagami, Naohito Yamamoto, Katsumasa Kuroi, Hirofumi Suwa, Shoichiro Ohtani, Toshikazu Ito, Shinji Yasuno, Satoshi Morita, Shinji Ohno, Masakazu Toi
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 12 (2018)
Background: There are little data on the usefulness of trastuzumab (TZM) retreatment as the first-line treatment for patients with HER2 (human epidermal growth factor receptor 2)–positive breast cancer recurrence after perioperative treatment with
Externí odkaz:
https://doaj.org/article/22b2fb940c0f411cb8432e5a38f4cbc2